SANXING(SH:601567) Chang Jiang Shang Bao·2025-08-25 00:31Core Viewpoint - Samsung Medical demonstrates robust performance growth driven by the synergy of its dual main businesses: "power grid equipment + medical services" [1][4] Group 1: Financial Performance - In the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, a year-on-year increase of 13.93% [1] - The net profit attributable to shareholders reached 1.23 billion yuan, reflecting a year-on-year growth of 6.93% [1] - The company plans to distribute a cash dividend of 4.85 yuan per 10 shares, totaling approximately 679 million yuan, with a dividend payout ratio of 55.20% [5] Group 2: Business Segments - Samsung Medical's overseas business experienced explosive growth, with total orders on hand reaching 17.632 billion yuan, a year-on-year increase of 18.39%, and overseas distribution orders at 2.182 billion yuan, up 123.96% [3][4] - The company reported overseas operating revenue of 1.495 billion yuan, marking a year-on-year increase of 50.89%, becoming a key driver of performance growth [3][4] - The medical services segment generated operating revenue of 3.258 billion yuan in 2024, reflecting a year-on-year growth of 12.69% [5] Group 3: Innovation and R&D - Samsung Medical invests over 5% of its revenue annually in research and development, fostering a complete independent innovation system [5][6] - R&D expenses from 2020 to 2024 were 313 million yuan, 294 million yuan, 327 million yuan, 471 million yuan, and 523 million yuan, with 257 million yuan in the first half of 2025 [6] - The company enhances its medical services through the introduction of advanced international medical technologies and equipment, particularly in rehabilitation medicine [6]